Authors: Desmedt M, Vertriest S, Hellings J, Bergs J, Dessers E, Vankrunkelsven P, Vrijhoef H, Annemans L, Verhaeghe N, Petrovic M, Vandijck D
Value Health. 2016 Sep - Oct;19(6):892-902
OBJECTIVES: To assess the costs and potential financial benefits of integrated care models for patients with chronic diseases, that is, type 2 diabetes mellitus, schizophrenia, and multiple sclerosis, respectively.
METHODS: A systematic search of the literature was performed using EMBASE, MEDLINE, and Web of Science. Studies that conducted a cost analysis, considered at least two components of the chronic care model, and compared integrated care with standard care were included.
RESULTS: Out of 575 articles, 26 were included. Most studies examined integrated care models for type 2 diabetes mellitus (n = 18) and to a lesser extent for schizophrenia (n = 6) and multiple sclerosis (n = 2). Across the three disease groups, the incremental cost per patient per year ranged from - â¬3860 to + â¬613.91 (xÂ¯ = - â¬533.61 Â± â¬902.96). The incremental cost for type 2 diabetes mellitus ranged from - â¬1507.49 to + â¬299.20 (xÂ¯ = - â¬518.22 Â± + â¬604.75), for schizophrenia from - â¬3860 to + â¬613.91 (xÂ¯ = - â¬677.21 Â± + â¬1624.35), and for multiple sclerosis from - â¬822 to + â¬339.43 (xÂ¯ = - â¬241.29 Â± + â¬821.26). Most of the studies (22 of 26 [84.6%]) reported a positive economic impact of integrated care models: for type 2 diabetes mellitus (16 of 18 [88.9%]), schizophrenia (4 of 6 [66.7%]), and multiple sclerosis (1 of 2 [50%]).
CONCLUSIONS: In this systematic literature review, predominantly positive economic impacts of integrated care models for patients with chronic diseases were found.